Online citations, reference lists, and bibliographies.
← Back to Search

Pan-FGFR Inhibition Leads To Blockade Of FGF23 Signaling, Soft Tissue Mineralization, And Cardiovascular Dysfunction.

G. Yanochko, A. Vitsky, J. R. Heyen, B. Hirakawa, J. Lam, J. May, T. Nichols, F. Sace, D. Trajkovic, E. Blasi
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The fibroblast growth factor receptors (FGFR) play a major role in angiogenesis and are desirable targets for the development of therapeutics. Groups of Wistar Han rats were dosed orally once daily for 4 days with a small molecule pan-FGFR inhibitor (5mg/kg) or once daily for 6 days with a small molecule MEK inhibitor (3mg/kg). Serum phosphorous and FGF23 levels increased in all rats during the course of the study. Histologically, rats dosed with either drug exhibited multifocal, multiorgan soft tissue mineralization. Expression levels of the sodium phosphate transporter Npt2a and the vitamin D-metabolizing enzymes Cyp24a1 and Cyp27b1 were modulated in kidneys of animals dosed with the pan-FGFR inhibitor. Both inhibitors decreased ERK phosphorylation in the kidneys and inhibited FGF23-induced ERK phosphorylation in vitro in a dose-dependent manner. A separate cardiovascular outcome study was performed to monitor hemodynamics and cardiac structure and function of telemetered rats dosed with either the pan-FGFR inhibitor or MEK inhibitor for 3 days. Both compounds increased blood pressure (~+ 17 mmHg), decreased heart rate (~-75 bpm), and modulated echocardiography parameters. Our data suggest that inhibition of FGFR signaling following administration of either pan-FGFR inhibitor or MEK inhibitor interferes with the FGF23 pathway, predisposing animals to hyperphosphatemia and a tumoral calcinosis-like syndrome in rodents.
This paper references
Toxicity of the fibroblast growth factor inhibitor, PD 176067, in juvenile and adult dogs
K. Datta (2003)
10.1038/36285
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
M. Kuroo (1997)
10.1016/j.bone.2012.05.015
FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway
O. Andrukhova (2012)
10.1152/ajpendo.00596.2012
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.
C. Touchberry (2013)
10.1158/1078-0432.CCR-11-1747
Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
K. Kim (2011)
Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis
A. Brown (2005)
10.1681/ASN.2012010048
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.
H. Olauson (2012)
10.1016/J.MATBIO.2004.09.007
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
D. Sitara (2004)
10.1038/ki.2009.24
Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase.
Mutsuko Ohnishi (2009)
10.1152/ajprenal.90742.2008
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
J. Gattineni (2009)
Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs
H. D. Beer (2000)
10.1172/JCI19081
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
T. Shimada (2004)
Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1.
A. Chellaiah (1994)
Regulation of phosphate transport.
K. Hruska (1997)
10.1038/nrc2780
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
10.1152/AJPHEART.00305.2002
Structural, functional, and molecular characterization of the SHHF model of heart failure.
J. Heyen (2002)
10.1172/JCI46122
FGF23 induces left ventricular hypertrophy.
C. Faul (2011)
10.1046/J.1523-1755.2001.00781.X
Fibroblast growth factor receptors and their ligands in the adult rat kidney.
B. Cancilla (2001)
10.1146/annurev.med.051308.111339
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.
C. Bergwitz (2010)
10.1111/J.1523-1755.2004.66013.X
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
K. Neves (2004)
10.1093/annonc/mdq599
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
D. Jonker (2011)
10.1185/03007995.2011.590970
Nitric oxide and adverse events of vascular endothelial growth factor inhibitors
J. Thachil (2011)
Fundamentals of Veterinary Clinical Pathology
S. Stockham (2002)
10.1038/nature05315
Klotho converts canonical FGF receptor into a specific receptor for FGF23
I. Urakawa (2006)
10.1038/nrd2792
The FGF family: biology, pathophysiology and therapy
A. Beenken (2009)
10.1016/0014-5793(93)80882-U
A novel form of FGF receptor‐3 using an alternative exon in the immunoglobulin domain III
A. Avivi (1993)
10.1007/s00467-009-1273-z
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism
J. Gattineni (2009)
10.1080/01926230590961845
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Alan P. Brown (2005)
10.1210/en.2011-1831
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
M. Y. Zhang (2012)
10.1074/jbc.275.21.16091
Fibroblast Growth Factor (FGF) Receptor 1-IIIb Is a Naturally Occurring Functional Receptor for FGFs That Is Preferentially Expressed in the Skin and the Brain*
H. D. Beer (2000)
10.1111/j.1755-5922.2011.00278.x
Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
E. Blasi (2012)
10.1002/9780470571224.PSE266
Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug‐Induced Systemic Mineralization: Case Study with a MEK Inhibitor
A. Brown (2010)
10.1681/ASN.2008070783
Initial FGF23-mediated signaling occurs in the distal convoluted tubule.
E. Farrow (2009)
Phosphate dysregulation following pan-FGFR inhibition in rodents
A. Vitsky (2011)
10.1093/toxsci/kfr263
Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney.
Dolores Diaz (2012)
10.1111/j.1440-1827.1955.tb01760.x
Urinary System
G. Rusak (1955)
10.2353/AJPATH.2006.060329
Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.
D. Sitara (2006)
10.1177/0192623309357950
Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition
A. M. Fletcher (2010)
10.1152/ajpendo.00499.2010
Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
H. Li (2011)
10.1681/ASN.2007121301
FGFR3 and FGFR4 do not mediate renal effects of FGF23.
S. Liu (2008)
10.1007/S11864-007-0022-4
Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors
Elwyn C. Cabebe (2007)
10.1074/jbc.C500457200
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*
H. Kurosu (2006)
10.1007/s00424-008-0580-8
Regulation of phosphate transport in proximal tubules
J. Biber (2008)
10.1161/01.RES.87.7.E10
Phosphate regulation of vascular smooth muscle cell calcification.
S. Jono (2000)
10.1002/jbmr.401
Fibroblast growth factor 23 regulates renal 1,25‐dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice
Daniel Ranch (2011)
10.1158/1078-0432.CCR-11-0699
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. N. Brooks (2012)



This paper is referenced by
10.1080/13543784.2017.1316714
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
E. Rijavec (2017)
Renal FGFR 1 signaling and blood pressure regulation 1
M. Publishers (2018)
Mechanisms of soft-tissue mineralization induced by the inhibition of the MEK/ERK pathway or the inhibition of fibroblast growth factor receptors
João A Graça (2016)
10.1016/j.cmet.2015.09.002
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
A. Grabner (2015)
10.3389/fendo.2018.00351
FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
R. Stoehr (2018)
10.1158/1078-0432.CCR-19-2035
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
F. Facchinetti (2019)
10.2215/CJN.10941013
The use of fibroblast growth factor 23 testing in patients with kidney disease.
E. Smith (2014)
RedesigningaMonospeci fi cAnti-FGFR 3 Antibody to Add Selectivity for FGFR 2 and Expand Antitumor Activity
Yiyuan Yin (2015)
10.1038/s41598-017-02068-6
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
A. Grabner (2017)
10.1001/jamadermatol.2018.4070
Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor.
D. Carr (2019)
10.1371/journal.pone.0134317
A Pan-GTPase Inhibitor as a Molecular Probe
L. Hong (2015)
10.1002/9781119187547.ch13
Development of Serum Calcium and Phosphorus as Safety Biomarkers for Drug‐Induced Systemic Mineralization: Case Study with the MEK Inhibitor PD 0325901 1
Alan P. Brown (2020)
Off-target effects and adverse outcomes of fibroblast growth factor 23 in chronic kidney disease
G. D. Marco (2018)
10.1002/path.5340
Repurposing an anti‐cancer agent for the treatment of hypertrophic heart disease
Matthew S Dukinfield (2019)
10.1152/ajprenal.00606.2015
FGF23 from bench to bedside.
C. Kovesdy (2016)
10.1007/s40620-020-00715-2
Fibroblast growth factor 23: are we ready to use it in clinical practice?
Annet Bouma-de Krijger (2020)
10.3389/fendo.2018.00422
Corrigendum: FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
R. Stoehr (2018)
10.1093/ndt/gfu190
Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
G. D. di Marco (2014)
10.1177/1758835920940948
Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
J. Wang (2020)
10.1007/s11523-017-0502-9
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
M. Michael (2017)
10.1016/j.lungcan.2019.12.018
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
10.1158/1535-7163.MCT-14-1050
Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Y. Yin (2015)
10.1007/s00467-019-04437-x
Genetic renal disease classification by hormonal axes
Bar Rotem-Grunbaum (2019)
10.2340/00015555-3438
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal.
Daniel Lopez-Castillo (2020)
10.1080/13543784.2020.1838484
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics
S. Chandana (2020)
10.1016/j.ebiom.2015.05.028
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
G. Kolumam (2015)
10.1158/0008-5472.CAN-19-2568
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome (2020)
10.1002/mnfr.201500409
Oral administration of oleuropein attenuates cisplatin-induced acute renal injury in mice through inhibition of ERK signaling.
Iva Potočnjak (2016)
10.1007/s11892-020-01335-7
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
Stanley M H Yeung (2020)
10.3382/ps/pez353
Effect of anti-fibroblast growth factor receptor 1 antibodies on phosphorus metabolism in laying hens and their progeny chicks.
Z. Ren (2019)
10.1158/1535-7163.MCT-16-0518
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Jayaprakash D Karkera (2017)
10.1016/j.taap.2020.115215
A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates.
P. Yu (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar